A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD: November 2022

I am thrilled to announce that I will be staying on as Editor in Chief of Oncology Data Advisor for at least another year. It gives me such great joy to work with such an accomplished group of experts in oncology, as well as with an extremely professional core of editors headed up by Keira Smith. We have grand plans for 2023. In the meantime, please avail yourselves of some of the best commentary in oncology today. I want to especially recommend two of our offerings that have recently hit the we...

Continue reading

Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. 

Continue reading

Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.  

Continue reading

Confronting Educational Needs in Treatment of Myelofibrosis

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for the management and treatment of patients with myelofibrosis. Myelofibrosis, considered a form of chronic leukemia, is a rare type of myeloproliferative neoplasm. An estimated one-third of individuals who have myelofibrosis will not show any symptoms in the early stages of the disorder, which can last many years. However, as the disease develops, they will begin to exhibit symptoms s...

Continue reading

Pacritinib Approved for Intermediate- or High-Risk Myelofibrosis With Thrombocytopenia

The FDA has approved pacritinib (VonjoTM, CTI BioPharma) for the treatment of adult patients with intermediate- to high-risk primary or secondary myelofibrosis with a platelet count below 50x109/L. Pacritinib is a novel oral kinase inhibitor which inhibits Janus kinase 2 (JAK2) with minimal myelosuppression. Previous treatments available for intermediate- and high-risk myelofibrosis have not been approved for patients with severe cytopenia. "Pacritinib can provide a treatment option for patients...

Continue reading

Evaluating Symptoms and Treatment Options for Myelofibrosis: Alice Lynn, ANP, and Dawn Urbanovsky, RN, BSN, OCN®

Myelofibrosis, a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis, is a very challenging disease to treat, with patients experiencing progressive symptoms that can negatively impact their quality of life. In this excerpt of the transcript from their nursing continuing professional development (NCPD)-approved activity, Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life, Alice Lynn, ANP, an...

Continue reading

Addressing Gaps in Knowledge of the Optimal Approach to Managing Myelofibrosis

Myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocytopenia, affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. Due to difficulties in identifying the disease, low disease prevalence, a complicated symptom profile, differences in patient and provider perspectives regarding symptom burden and treatment goals, and a lack of effective and tolerable therapies, there is confusion over the optimal approach to t...

Continue reading

Fedratinib for Improved Quality of Life in Myelofibrosis With Ruben Mesa, MD

Patients with myelofibrosis can experience debilitating symptoms that negatively impact their quality of life. In the phase 3 JAKARTA trial, a team of researchers led by Ruben Mesa, MD, the Director of MD Anderson Cancer Center at the University of Texas, San Antonio, found that fedratinib, an oral JAK2 inhibitor, decreased symptom severity and markedly improved quality of life in patients with intermediate- or high-risk primary or secondary myelofibrosis. Dr. Mesa presented the results of the t...

Continue reading

Fedratinib Approved for Myelofibrosis

​The FDA has now approved fedratinib (Inrebic®, Impact Biomedicines, Inc./Celgene Corporation) for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis. A myeloproliferative neoplasm, myelofibrosis can either present as a primary condition or as a secondary condition following the transformation of polycythemia vera or essential thrombocythemia. Myelofibrosis causes anemia, splenomegaly, and debilitating symptoms, and it shortens survival. "Prior to today, there was on...

Continue reading

When Should Ruxolitinib Be Used for Myelofibrosis or PV? With Srdan Verstovsek, MD, PhD

Myelofibrosis, a rare myeloproliferative neoplasm, can cause severe anemia, splenomegaly, and debilitating symptoms. It can present either as a primary condition or as a secondary condition following the transformation of essential thrombocythemia or polycythemia vera (PV), a slow-growing blood cancer in which the bone marrow produces an excess of red blood cells and often of white blood cells and platelets. Last week at the Society of Hematologic Oncology (SOHO)'s Seventh Annual Meeting, Srdan ...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.